^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + nintedanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma
Published date:
11/09/2021
Excerpt:
Patients with aMM relapsing after at least one line of platinum doublet chemotherapy and not previously pre-exposed to IO were treated with a combination of oral nintedanib (150mg BID) & IV pembrolizumab (200mg Q3W) with a 7 days nintedanib lead-in preceding pembrolizumab initiation....Patients with DCR at 6 months had significantly higher percentage of PDL1 expression on tumor cells (by Immuno-Histo-Chemistry, antibody clone SP263)...
DOI:
http://dx.doi.org/10.1136/jitc-2021-SITC2021.378
Trial ID:
